Avenue Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATXI research report →
About the company
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery.
- CEO
- Alexandra MacLean
- IPO
- 2017
- Employees
- 2
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $1.00M
- P/E
- -0.58
- P/S
- 0.72
- P/B
- 0.84
- EV/EBITDA
- 0.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -149.29%
- Net Margin
- -124.79%
- ROE
- -65.83%
- ROIC
- -182.74%
- Revenue
- $1.40M · 0.00%
- Net Income
- $-2,909,000 · 75.03%
- EPS
- $-0.93 · -3.33%
- Op Income
- $-3,286,000
- FCF YoY
- 79.69%
- 52W High
- $0.97
- 52W Low
- $0.15
- 50D MA
- $0.37
- 200D MA
- $0.49
- Beta
- -0.17
- Avg Volume
- 2.88K
Get TickerSpark's AI analysis on ATXI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 26 | Fortress Biotech, Inc. | other | 111,209 |
| Mar 31, 25 | Fortress Biotech, Inc. | other | 33,724 |
| Dec 31, 24 | Fortress Biotech, Inc. | other | 0 |
| Dec 2, 24 | Herskowitz Neil | sell | 23 |
| Nov 5, 24 | KRANZLER JAY D | sell | 61 |
| Sep 30, 24 | KRANZLER JAY D | buy | 497 |
| Sep 27, 24 | KRANZLER JAY D | buy | 3 |
| Sep 23, 24 | ROSENWALD LINDSAY A MD | other | 30,000 |
| Sep 23, 24 | Herskowitz Neil | other | 30,000 |
| Sep 23, 24 | Oltmans Curtis Gale | other | 30,000 |
Our ATXI coverage
Recent articles, reports, and earnings notes.
No research on ATXI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATXI report →Similar companies
Peers in the same neighborhood.